Cytokinetics (CYTK) Restructuring Costs (2012)
Cytokinetics (CYTK) posted quarterly Restructuring Costs of -$2000.0 for Q3 2012, up 84.62% quarter-over-quarter from -$13000.0 in Q2 2012.
Powered by 
Analysis
Cytokinetics (CYTK) Restructuring Costs (2012) Analysis & Trends
Cytokinetics (CYTK) has reported Restructuring Costs for 1 consecutive years, with -$2000.0 the latest figure, recorded in Q3 2012.
- In Q3 2012, Restructuring Costs changed N/A year-over-year to -$2000.0; the TTM figure through Dec 2012 stood at -$56000.0 (changed N/A YoY), while the FY2012 annual figure was -$56000.0, down 104.7% from the prior year.
- Restructuring Costs grew to -$2000.0 in Q3 2012 per CYTK's latest filing, from -$13000.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at -$2000.0 in Q3 2012 and bottomed at -$41000.0 in Q1 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2012 | -2,000.00 |
| Jun 30, 2012 | -13,000.00 |
| Mar 31, 2012 | -41,000.00 |